Videos

Dr Ericka Wong discusses recent FDA approval of efgartigimod for myasthenia gravis.

Ericka Wong, MD, discusses challenges and opportunities with new FDA-approved treatments for myasthenia gravis.

The associate neurologist-in-chief at Boston Children’s Hospital provided insight on the treatment decisions clinicians make for patients with SMA and the challenges with improving optimization. [WATCH TIME: 3 minutes]

Dr Flavia Nelson comments on the impact of S1P modulators on brain volume measures; highlighting thalamic atrophy and its correlation with brain volume loss in MS.

Experts in neurology review data surrounding the role of disease-modifying therapies in preventing grey matter brain atrophy and cognitive decline.

The associate neurologist-in-chief at Boston Children’s Hospital discussed the importance of defining and acting on spinal muscular atrophy in its presymptomatic stages. [WATCH TIME: 4 minutes]

Dr Macaron shares her interpretation of the data and importance of individualizing treatment for patients with multiple sclerosis.

Dr Gabrielle Macaron reviews data with ozanimod in treatment naïve vs experienced patients with relapsing multiple sclerosis presented at EAN 2022.

A multiple sclerosis expert, Dr Gabrielle Macaron, discusses factors that can lead to a change of therapy for patients with multiple sclerosis.

Chaired by Annette Okai, MD, of North Texas Institute of Neurology & Headache, the presentations also feature Fernando Cuascut, MD, MPH, of Baylor College of Medicine; and Lauren Tardo, MD, and Rebecca Romero, MD, of UT Southwestern Medical Center. [WATCH TIME: 1 hour, 18 minutes]

The associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center discussed the ways clinicians go about properly prescribing exercise regimens for patients with spinal muscular atrophy. [WATCH TIME: 3 minutes]

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, deliver parting thoughts on the state of the myasthenia gravis treatment, focusing on current deficits and future prospects.

Two subject matter experts discuss promising treatment methods and agents in the pipeline for patients with myasthenia gravis.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami detailed a new international initiative that expands on the genetic backgrounds of people of Hispanic and African ancestry. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending July 23, 2022. [WATCH TIME: 4 minutes]

The associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center provided insight on the tools and gaps in care for assessing physical capacity in patients with spinal muscular atrophy. [WATCH TIME: 4 minutes]

Joseph E. Sullivan, MD, leads a discussion on treatment options for the management of patients with LGS and considers the impact of treatment on quality of life.

Kelly Knupp, MD, shares her perspective of a provider journey of a new patient with LGS and goal setting to manage the disease.

An expert neurologist discusses the clinical use of ravulizumab in the treatment of myasthenia gravis.

Dr Ericka Wong discusses the approval of eculizumab in the treatment of myasthenia gravis.

Amit Bar-Or, MD, FRCPC, discusses the potential impact vaccination against Epstein-Barr virus could play on multiple sclerosis rates, highlighting recent investigations.

Experts in neurology discuss screening and diagnostic considerations for a patient newly diagnosed with multiple sclerosis.

Dr Kita Williams shares how she manages patients in her migraine practice.

A migraine specialist discusses advantages of multidisciplinary team approach to managing patients with migraine.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared towards understanding genetic differences of underrepresented groups. [WATCH TIME: 6 minutes]

Jeffrey Dunn, MD, and Regina Berkovich, MD, PhD, share advice for building trust and individualizing treatment approaches in ethnically diverse and underrepresented patient populations with multiple sclerosis.

Jeffrey Dunn, MD, and Regina Berkovich, MD, PhD, highlight the role of a multidisciplinary care team in engaging ethnically diverse and underrepresented patient populations with multiple sclerosis in clinical trials and practice.

Dr Heidi Crayton discusses the role of S1P receptor modulators in the management of patient with multiple sclerosis.

Flavia Nelson, MD, provides an overview of available brain atrophy data and cognition research in patients with multiple sclerosis.

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the state of treatment for status migrainosus and whether or not the new migraine medications can help improve care. [WATCH TIME: 2 minutes]